ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Neoadjuvant nivolumab with or without platinum-doublet chemotherapy based on PD-L1 expression in resectable NSCLC (CTONG1804): a multicenter open-label phase II study

Liu, Si-Yang; Dong, Song; Yang, Xue-Ning; Liao, Ri-Qiang; Jiang, Ben-Yuan; Wang, Qun; Ben, Xiao-Song; Qiao, Gui-Bin; Lin, Jun-Tao; Yan, Hong-Hong; Yan, Li-Xu; Nie, Qiang; Tu, Hai-Yan; Wang, Bin-Chao; Yang, Jin-Ji; Zhou, Qing; Li, Hong-Rui; Liu, Ke; Wu, Wendy; Liu, Si-Yang Maggie; Zhong, Wen-Zhao*; Wu, Yi-Long*复旦大学; 广东省人民医院; 南方医科大学; 1
Signal Transduction and Targeted Therapy2023-12-6DOI: 10.1038/s41392-023-01700-4
4阅读
引用收藏
分享

摘要

This prospective multicenter phase II study evaluated the clinical efficacy of neoadjuvant nivolumab-exclusive (N) and nivolumab-chemotherapy (N/C) combinations based on PD-L1 expression. Eligible patients exhibited resectable clinical stage IIA-IIIB (AJCC 8th edition) NSCLC without EGFR/ALK alterations. Patients received either mono-nivolumab (N) or nivolumab + nab-paclitaxel+ carboplatin (N/C) for three cycles based on PD-L1 expression. The primary endpoint was the major pathological response (MPR). Key secondary endpoints included the pathologic complete response (pCR), objective response rate (ORR), and event-free survival (EFS). Baseline PD-L1 expression and perioperative circulating tumor DNA (ctDNA) status were correlated with pCR and EFS. Fifty-two patients were enrolled, with 46 undergoing surgeries. The MPR was 50.0% (26/52), with 25.0% (13/52) achieving pCR, and 16.7% and 66.7% for patients with PD-L1 >= 50% in N and N/C groups, respectively. Thirteen (25.0%) patients experienced grade 3 or higher immune-related adverse events during neoadjuvant treatment. Patients with post-neoadjuvant ctDNA negativity was more likely to have pCR (39.1%) compared with those remained positive (6.7%, odds ratio = 6.14, 95% CI 0.84-Inf, p = 0.077). With a median follow-up of 25.1 months, the 18-month EFS rate was 64.8% (95% CI 51.9-81.0%). For patients with ctDNA- vs. ctDNA + , the 18m-EFS rate was 93.8% vs 47.3% (HR, 0.15; 95% CI 0.04, 0.94; p = 0.005). Immunochemotherapy may serve as an optimal neoadjuvant treatment even for patients with PD-L1 expression >= 50%. ctDNA negativity following neoadjuvant treatment and surgery could help identify superior pathological and survival benefits, which requires further confirmation in a prospective clinical trial (NCT04015778).

学科与关键词

关键词
CELL LUNG-CANCERPREOPERATIVE CHEMOTHERAPYPLUS CHEMOTHERAPY2-STAGE DESIGNSSINGLE-ARMIMMUNOTHERAPYSURGERYEFFICACYTRIALCTDNA
相关
加载中…
  • Neoadjuvant Camrelizumab for Non-Small Cell Lung Cancer: A Retrospective Multicenter, Real-World Study (CTONG2004)
    Liu, Si-Yang; Chen, Qixun; Zhou, Chengzhi; Zhang, Huizhong; Li, Wen; Chen, Jianhua; Hu, Jian; Wu, Lin; Chen, Qunqing; Dai, Qiangsheng; Shan, Jian-Zhen; Xu, Fei; Liu, Si-Yang Maggie*; Wu, Yi-Long*Cancer Immunology, Immunotherapy, 2023, 72(7): 2257-2265.被引 3
  • Induction immune-checkpoint inhibitors for resectable oncogene-mutant NSCLC: A multicenter pooled analysis
    Zhang, Chao; Chen, Hua-Fei; Yan, Shi; Wu, Lin; Yan, Li-Xu; Yan, Xiao-Long; Yue, Dong-Sheng; Xu, Chun-Wei; Zheng, Min; Li, Ji-Sheng; Liu, Si-Yang; Yang, Ling-Ling; Jiang, Ben-Yuan; Ou, Qiu-Xiang; Qiu, Zhen-Bin; Shao, Yang; Wu, Yi-Long; Zhong, Wen-Zhao*npj Precision Oncology, 2022, 6(1): 66.被引 10
  • Neoadjuvant immunotherapy for non-small cell lung cancer: State of the art
    Kang, Jin; Zhang, Chao; Zhong, Wen-Zhao*Cancer Communications, 2021, 41(4): 287-302.被引 62
查看全部 →

发表信息

论文状态
公开发表
期刊
Signal Transduction and Targeted Therapy
发表日期
2023-12-06
卷期
第 8 卷, 第 1 期
页码
442
DOI
10.1038/s41392-023-01700-4
期刊收录
CAST-L
成果收录
SCIE
资助标注
This work was supported by the Chinese Thoracic Oncology Group (CTONG 1804); and Bristol Myers Squibb (grant number BMSCA209-8D8). ctDNA analysis was performed by the Berry Oncology Corporation and Fujian Key Laboratory of Advanced Technology for Cancer Sc [BMSCA209-8D8]; Bristol Myers Squibb [CTONG1804]; Chinese Thoracic Oncology Group; Fujian Key Laboratory of Advanced Technology; Berry Oncology Corporation

作者

  • L

    Liu, Si-Yang (第一作者)

  • D

    Dong, Song

    guangdong prov peoples hosp · southern med univ

查看全部 22 位作者收起作者
  • Y

    Yang, Xue-Ning

    guangdong prov peoples hosp · southern med univ

  • L

    Liao, Ri-Qiang

    guangdong prov peoples hosp · southern med univ

  • J

    Jiang, Ben-Yuan

    guangdong prov peoples hosp · southern med univ

  • W

    Wang, Qun

    fudan univ

  • B

    Ben, Xiao-Song

    guangdong prov peoples hosp · southern med univ

  • Q

    Qiao, Gui-Bin

    guangdong prov peoples hosp · southern med univ

  • L

    Lin, Jun-Tao

    guangdong prov peoples hosp · southern med univ

  • Y

    Yan, Hong-Hong

    guangdong prov peoples hosp · southern med univ

  • Y

    Yan, Li-Xu

    guangdong prov peoples hosp · southern med univ

  • N

    Nie, Qiang

    guangdong prov peoples hosp · southern med univ

  • T

    Tu, Hai-Yan

    guangdong prov peoples hosp · southern med univ

  • W

    Wang, Bin-Chao

    guangdong prov peoples hosp · southern med univ

  • Y

    Yang, Jin-Ji

    guangdong prov peoples hosp · southern med univ

  • Z

    Zhou, Qing

    guangdong prov peoples hosp · southern med univ

  • L

    Li, Hong-Rui

  • L

    Liu, Ke

  • W

    Wu, Wendy

  • L

    Liu, Si-Yang Maggie

  • Z

    Zhong, Wen-Zhao (通讯)

    guangdong prov peoples hosp · southern med univ

  • W

    Wu, Yi-Long (通讯)

    guangdong prov peoples hosp · southern med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417